Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension-Reference-Cited by-同舟云学术

Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension

Published:2022-10 Issue: Volume:248 Page:271-278
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Kane John M.,Kinon Bruce J.,Forray Carlos,Such Pedro,Mittoux Aurélia,Lemming Ole M.,Hertel Peter,Howes Oliver D.

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference23 articles.

1. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients;Davis;Acta Psychiatr. Scand.,2014

2. Clozapine's multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia;de Bartolomeis;Pharmacol. Ther.,2022

3. Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia;Den Boer;Psychopharmacology,1995

4. Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia. EMA/CHMP/40072/ 2010 Rev 1,2012

5. Distal kinetic deuterium isotope effect: phenyl ring deuteration attenuates N-demethylation of Lu AF35700;Gjervig Jensen;Bioorg. Med. Chem. Lett.,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis;Expert Review of Clinical Pharmacology;2024-01-26

2. Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia;International Journal of Neuropsychopharmacology;2024-01-09

3. Lu AF35700 reverses the phencyclidine-induced disruption of thalamo-cortical activity by blocking dopamine D1 and D2 receptors;European Journal of Pharmacology;2023-08

4. Recent Advances in Psychopharmacology: From Bench to Bedside Novel Trends in Schizophrenia;Journal of Personalized Medicine;2023-02-25